OBJECTIVES: Small-cell lung carcinoma (SCLC) and large-cell neuroendocrine carcinoma (LCNEC) are categorized as high-grade neuroendocrine tumours because of their poor prognosis compared with those of other neuroendocrine tumours of the lung. There have been no clinicopathological studies focusing on small-sized high-grade neuroendocrine tumours. We analysed clinicopathological features of peripheral, small-sized high-grade neuroendocrine tumours of the lung retrospectively.
A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma 
INTRODUCTION
Neuroendocrine (NE) tumours of the lung were defined as four major subtypes, namely typical carcinoid, atypical carcinoid, large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC), by the World Health Organization (WHO) classification published in 1999 [1] and that revised in 2004 became more precision in the differential diagnosis between LCNEC and SCLC [2] . SCLC is the most aggressive lung cancer because it grows rapidly and metastasizes early to regional lymph nodes and distant organs [3] . For the therapy of SCLC, surgical treatment alone is greatly restricted because of poor outcome, and now, surgical treatment with adjuvant chemotherapy is generally used on selected patients with a very early stage of the disease [4, 5] .
On the other hand, LCNEC is also known to be highly malignant, and affected patients show significantly shorter survival than those with non-small-cell lung carcinoma (NSCLC) [6, 7] . For the therapy of LCNEC, combined modality therapy including surgery and adjuvant chemotherapy of the same regimens as SCLC has been reported recently because of its poor prognosis similar to that of SCLC [8, 9] . Both SCLC and LCNEC are not only categorized as high-grade NE tumours, but also resemble each other from the viewpoint of poor outcomes and several biological features characterized by microarray analysis [10] . However, some researchers have insisted that SCLC and LCNEC are morphologically and phenotypically different tumours [11, 12] , and it is still controversial to use the same strategy of treatment for both SCLC and LCNEC.
There have been few comparative clinicopathological studies between SCLC and LCNEC. Moreover, the clinicopathological findings and the prognoses of small-sized high-grade NE tumours have not been evaluated yet. Therefore, we collected the data of small-sized high-grade NE tumours in a single institution and aimed to identify clinicopathological differences between SCLC and LCNEC.
PATIENTS AND METHODS
From September 2002 to March 2010, 1235 patients underwent surgery for primary lung cancer at the Shizuoka Cancer Center. Of these, 44 patients had high-grade NE tumours, in which 20 patients had SCLC and 24 patients had LCNEC. In this study, we selected 28 tumours with peripheral location, small in size (3 cm or less in diameter) and at an early stage (clinical-stage I or II) from these 44 tumours retrospectively. We excluded the disease with the tumour which was larger than 3 cm in diameter, clinical N2 (the criterion was mediastinal lymph node of size more than 1.0 cm in the short axis on a CT image), pleural dissemination and distant metastasis. Staging was done according to the Seventh International tumor, node, metastasis (TNM) staging system [13, 14] . We performed lobectomy or pneumonectomy, with lymph node dissection as the standard surgical treatment. Wedge resection or segmentectomy was performed for only the patients with impairment of pulmonary function. In adjuvant treatment, all SCLC patients were given adjuvant chemotherapy consisting of four cycles of cisplatin or carboplatin and etoposide when possible. However, we performed adjuvant chemotherapy for LCNEC patients as NSCLC basically (i.e. no adjuvant therapy for stage IA patients, tegafur-uracil for stage IB patients and cisplatin and vinorerbin for stage II and IIIA patients), and LCNEC patients were given adjuvant chemotherapy as only a pilot study consisting of cisplatin and etoposide or irinotecan during this period. Adjuvant prophylactic cerebral radiotherapy did not used in this study. All patients were enrolled in accordance with the regulations of the institutional review board.
To investigate the frequency of small-sized high-grade NE tumours, we also collected all inoperable and advanced highgrade NE tumours diagnosed by biopsy and cytology specimens during the same period as mentioned above and compared the tumour size with the above-mentioned operable high-grade NE tumours. With regard to the diagnosis of inoperable LCNEC, we included only tumours that were diagnosed using biopsy specimens showing histological features of large-cell carcinoma with NE morphology and immunohistochemical positivity for at least one NE marker and excluded tumours that were diagnosed using only cytology specimens or insufficient biopsy specimens. We think that these LCNEC cases diagnosed by biopsy specimens correspond to 'possible LCNEC cases' proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society classification for small biopsies [15] .
The histological diagnoses of SCLC and LCNEC were based on the revised WHO classification of lung carcinoma (2004) [2] . The histology of all tumours was reviewed by three of the authors (T.N., I.I. and R.W.) and a consensus diagnosis was reached. NE differentiation was identified by one or more positive immunohistochemical stainings for neural cell adhesion molecule (NCAM) (Zymed Technology Invitrogen, South San Francisco, CA, USA), chromogranin A (Dako, Glostrup, Denmark) and synaptophysin (SIGNET, Denver, CO, USA). Lymphatic and vessel involvements were confirmed by haematoxylin-eosin staining as well as immunostaining with D2-40 (Dako) and Elastic fibre stain. Representative photomicrographs of SCLC and LCNEC were shown in Fig. 1 .
Data extracted from each patient's medical record included age, sex, smoking history, tumour size, preoperative serum tumour marker levels, preoperative diagnosis, clinical and pathological TNM stage, operative procedure, pathological findings, adjuvant chemotherapy, recurrence and survival. Date of update survival was 30 January 2011. For serum tumour markers, three markers consisting of carcinoembryonic antigen (CEA; normal level <5 ng/ml), neuron-specific enolase (NSE; normal level <10 ng/ml) and progastrin-releasing peptide ( proGRP; normal level <46 ng/ml) were examined.
Statistical analysis
Patient characteristics and perioperative and pathological data were compared by Fisher's exact test. The data of age and tumour size were compared by Mann-Whitney U-test. Survival time and disease-free interval were calculated by the KaplanMeier method. The difference in survival between the two groups was analysed by the log-rank test. Statistical analysis results were considered to be significant when the probability value was <0.05. The analyses were performed with statistical software GraphPad Prism (Prism for Windows, Version 5.04, GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
The size of all high-grade NE tumours with and without surgery is summarized in Table 1 . Of all SCLC (273 cases), 44 cases (16%) were small-sized tumours and only 20 cases (7%) were surgically resected. Of all LCNEC (49 cases), 15 cases (31%) were smallsized tumours and 24 cases (49%) were surgically resected. With regard to surgically resected cases, 90% (18 of 20 cases) of SCLC were small-sized tumours. Meanwhile, 58% (10 of 24 cases) of LCNEC were >3 cm in diameter.
The clinical characteristics of the patients with small-sized tumours are summarized in Table 2 . There were no statistically significant differences between SCLC and LCNEC with respect to the age and sex of the patient, tumour diameter, smoking history, clinical stage or surgical procedure. The serum CEA level was elevated in half of the patients with SCLC and LCNEC. The serum NSE level was elevated in only one patient with SCLC. The serum proGRP level was elevated in five patients (28%) with SCLC, three of whom had lymph node metastases.
The preoperative diagnoses were performed using the specimens obtained by a transbronchial lung biopsy and are summarized in Table 3 , and 64% (18 of 28) of the patients were diagnosed with lung cancer. The preoperative diagnoses of 10 patients (eight of SCLC and two of LCNEC) were indeterminate due to insufficient biopsy specimens. Although 39% (7 of 18) of the cases of SCLC were correctly diagnosed, none of the LCNEC was correctly diagnosed preoperatively. The correct preoperative histological diagnosis was obtained more frequently in SCLC than in LCNEC (P = 0.03).
The postoperative pathological profiles of small-sized NE tumours are listed in Table 4 . Lymph node metastasis was seen in 44% of SCLC and 20% of LCNEC, but the difference was not statistically significant (P = 0.19). However, SCLC histologically showed a significantly higher incidence of lymphatic involvement than LCNEC (P = 0.013). Moreover, SCLC showed a significantly higher incidence of the presence of combined elements than LCNEC (P = 0.048). The prognoses of pure and combined SCLC showed no significant difference (median overall survival 40 months in pure SCLC versus 40 months in combined SCLC; P = 0.86).
There was no postoperative mortality in both SCLC and LCNEC groups. Postoperative morbidity was 39% in the SCLC group and 40% in the LCNEC group; however, there was no serious complication in both the groups.
As shown in Table 5 , postoperative adjuvant chemotherapy was administered to 94% (17 of 18) of the patients with SCLC and 20% (2 of 10) of those with LCNEC. The recurrence rate after complete resection was significantly higher in SCLC than in LCNEC (67% versus 20%; P = 0.0051). In spite of extensive therapy using radical surgery (lobectomy or pneumonectomy with lymph node dissection) and postoperative chemotherapy, SCLC recurred more frequently than LCNEC (90 versus 14%; P = 0.0037).
In the patients with small-sized NE tumours, the median follow-up time was 22 months (range, 4-83 months). In clinicalstage IA small-sized NE tumours, the 5-year survival rate of LCNEC patients was 100% (Fig. 2a) and the median survival time of SCLC was 40 months. There was a significant difference in overall survival between SCLC and LCNEC (P = 0.029). In clinical-stage IA small-sized NE tumours, the 2-year disease-free survival rates were 27% in SCLC and 73% in LCNEC, and the survival time of LCNEC was significantly longer than that of SCLC (P = 0.041) (Fig. 2b) . In pathological-stage IA small-sized NE tumours, the 5-year overall survival rate of LCNEC patients was also 100%. There was no significant difference in overall and disease-free survival between SCLC and LCNEC; however, the survival time of LCNEC tended to be longer than that of SCLC (median overall survival not yet reached in LCNEC versus 40 months in SCLC, and median disease-free survival not yet reached in LCNEC versus 11 months in SCLC).
DISCUSSION
In this retrospective study, we directly compared small-sized SCLC and LCNEC and evaluated their differences. There are a few reports describing the proportion of small-sized SCLC in all SCLC including extensive disease. Quoix et al. [16] reported that only 3% of all SCLC tumours were 3 cm or less in diameter and were found as a solitary pulmonary nodule in a peripheral zone. This study revealed that the frequency of small-sized tumours in all SCLC cases was 16%, and only 7% of SCLC underwent surgery. In contrast, there have been no reports on the size Figure 2 : In clinical-stage IA small-sized high-grade NE tumours, overall survival curves (a) and disease-free survival curves (b) are shown. There was a significant difference in overall survival between SCLC and LCNEC (P = 0.029, log-rank test). The disease-free survival time of LCNEC was also significantly longer than that of SCLC (P = 0.041, log-rank test). distribution of LCNEC including non-surgical cases to our knowledge. Our study revealed that the frequency of small-sized tumours in all LCNEC cases was 31%, and 49% of LCNEC underwent surgery. The ratios of small-sized tumour to all resected SCLC and LCNEC were 90 and 42%, respectively. Most SCLC cases larger than 3.0 cm in diameter were inoperable, whereas more than half of resected LCNEC cases were >3 cm in diameter.
Our findings suggest that LCNEC is biologically less aggressive than SCLC. With regard to serum tumour markers, previous studies that were not concerned with tumour size reported that CEA level was elevated in 40.7% [17] of the patients with SCLC, and in 48.5% [17] or 50% [6] of the patients with LCNEC; NSE level was elevated in 2.3% [17] or 57.8% [18] of SCLC, and 12.4% [17] or 19% [6] of LCNEC; and proGRP was elevated in 48.5% [17] or 79.7% [18] of SCLC, and 25.8% [17] or 11% [6] of LCNEC. In spite of studying serum tumour markers only in small-sized tumours, CEA and proGRP were elevated in the patients with these tumours and were worth using as serum tumour markers, especially for SCLC, in this study. proGRP seems to be the best detector of small-sized SCLC.
In preoperative diagnosis of high-grade NE tumours, two studies reported that the correct diagnosis was obtained at a rate of 67% [19] or 35% [20] in SCLC. However, the proportion of clinical-stage IA patients of these studies was only 35%. In this study using small-sized tumours, the correct diagnoses were obtained in 39% of SCLC and 0% of LCNEC. Even if surgically resected tumours are used, correct diagnosis of LCNEC, especially differential diagnosis of LCNEC from SCLC, has remained problematic among pathologists, and preoperative diagnosis of small-sized high-grade NE tumours using biopsy or cytology specimens is still quite difficult [21, 22] .
Clinical N0 disease of SCLC was often underestimated and showed 20-25% of lymph node involvement after pathological investigation [5, 19] . Among clinical-stage IA disease, 33% of cases with SCLC and none with LCNEC had lymph node metastasis in this study. Our comparative study showed that the frequency of pathologically revealed lymphatic involvement in SCLC was significantly higher than that in LCNEC (94 versus 50%). Moreover, the serum NE tumour markers (NSE or proGRP) were elevated in 50% of SCLC with lymph node involvement. Therefore, when the serum NE tumour marker levels are elevated, it is recommended to check the lymph node by mediastinoscopy prior to resection even in patients with small-sized SCLC.
Poor prognosis of high-grade NE tumour was reported by several studies. In stage I disease of SCLC and LCNEC, the 5-year survival rates reported recently ranged from 36 to 58% [4, 17, 20] and from 33 to 67% [6, 9, 17, 23] , respectively, and no significant difference between SCLC and LCNEC was reported by the direct comparison of the prognosis [6, 17] . However, these stage I diseases included large-sized tumours in stage IB disease in previous TNM staging system [24] . There was a significant difference reported in the prognosis between T1 and T2 in both SCLC and NSCLC [14, 25] . In clinical-stage IA small-sized tumours, the 5-year survival rate of LCNEC patients was 100%, and there was a significant difference in overall and disease-free survival between SCLC and LCNEC in this study. Although our cases were small in number and were followed for a short period, the survival time of LCNEC tended to be longer than that of SCLC.
For SCLC, the therapeutic strategy for very limited-stage disease, that is, stage IA disease, was combined surgical resection and adjuvant chemotherapy because of its intense chemosensitivity and aggressive biological features [4, 5, 19, 20] . For LCNEC, the same strategy using adjuvant chemotherapy of the same regimen as for SCLC has been reported recently because LCNEC shows the same NE nature as SCLC and poor prognosis similar to SCLC [8, 9] . However, this study suggested that patients with small-sized LCNEC had a better prognosis than those with SCLC, although most LCNEC patients had no adjuvant chemotherapy. The prognostic difference in stage IA high-grade NE tumours should be considered in the case of postoperative adjuvant chemotherapy.
We are aware of the limitation of the small number of the cases and observed events. We cannot show definitive conclusion; however, in fact, the clinicopathological findings and the prognoses of small-sized high-grade NE tumours have not been evaluated yet. Further studies are needed to clarify the difference between SCLC and LCNEC in small-sized tumours.
CONCLUSION
There were several interesting differences in clinical and pathological findings between small-sized SCLC and LCNEC. Although there were some limitations, this study suggested that the prognosis of the patients with LCNEC tends to be better than that of those with SCLC in stage IA tumours. Therefore, it is necessary for the therapeutic strategy to be chosen in consideration of the differences between SCLC and LCNEC, as shown in small-sized tumour.
